TO: OLIVIER HENRY, PRESIDENT OF BIO-THERAPY REPORT LLCFROM: THE OFFICE OF THE PRESIDENT OF VERDUS PHARMACEUTICALSSUBJECT: THE HART STUDYDATE: NOVEMBER 1, 2007CC: ALL EMPLOYEES OF VERDUS PHARMACEUTICALS

Dear Mr. Henry,

This Memo shall confirm receipt of your Letter dated October 26th, 2007 in which you informed the Board ofDirectors of Verdus Pharmaceuticals that you will be suspending funding of the Hart Study and the LullabyeProject. While the early promise of Dr. Calvin Hart’s research was cause for our shared optimism andjubilation, the Board cannot deny the fact that all twenty of Dr. Hart’s Patients in Group A failed to reachmaturation and were therefore unable to be harvested.

The Board admits that the study was a failure, and that the long term viability of Dr. Hart’s geneticmodifications remain very much in doubt. However, all scientific theories must be put to the test, and theBoard roundly rejects your claim that “faulty” medical research or our “inexperienced personnel” aresomehow to blame. Verdus Pharmaceuticals is a proud family company with a rich tradition of pioneeringmedicine, and the Board stands behind all of our employees, many of whom will now have to be laid off.Finally, and most important, the Board asks you to consider the following:

Even in failure, we must celebrate the date, always grateful for science’s Impossible Puzzles and elegantsolutions, and knowing full well that our confederates will carry on this Historic Fight.So, let them always remember the first shot, the first name of war, and know well that it was yours.